Login
$BMRN
$57.99 +$0.76 (1.33%) Live

$BMRN 8-K/A SEC Filings

Filed On Filing
13 Jul 2026 8-K/A: Other Events

To the Stockholders and the Board of Directors of Amicus Therapeutics, Inc.

08 Aug 2016 8-K/A: Financial Statements and Exhibits

To Management Board and shareholders of Prosensa Holding N.V. in liquidatie

15 Mar 2016 8-K/A: Financial Statements and Exhibits

The following unaudited pro forma condensed combined financial statements of BioMarin Pharmaceutical Inc. (BioMarin) are presented to illustrate the effects of BioMarin’s acquisition of rights to the approved pharmaceutical product refer...

03 Apr 2015 8-K/A: Financial Statements and Exhibits

Total comprehensive loss is fully attributable to equity holders of the Company

10 Dec 2014 8-K/A: Entry into a Material Definitive Agreement

As an inducement to the Company’s and Buyer’s willingness to enter into the Purchase Agreement and commence the Offer, the Company and Buyer entered into tender and support agreements (the “Tender and Support Agreements”, the form of whi...

26 Aug 2014 8-K/A: Results of Operations and Financial Condition

On July 30, 2014, in connection with the Company’s press release announcing financial results for the second quarter ended June 30, 2014 (the Press Release), the Company announced its sale of the Rare Pediatric Disease Priority Review Vo...

28 Oct 2010 8-K/A: Completion of Acquisition or Disposition of Assets

Financial Statements and Report of Independent Certified Public Accountants

02 Apr 2010 8-K/A: Departure/Election of Directors or Officers; Compensation

c/o G. Eric Davis, Senior Vice President and General Counsel

06 Jul 2005 8-K/A: Entry into a Material Definitive Agreement; Departure/Election of Directors or Officers; Compensation

This DEVELOPMENT, LICENSE AND COMMERCIALIZATION AGREEMENT (“Agreement”) is made effective as of the 13th day of May, 2005 (the “Effective Date”) by and between BioMarin Pharmaceutical Inc., a corporation organized under the laws of Delaw...

06 Jul 2005 8-K/A: Entry into a Material Definitive Agreement

This License Agreement (hereinafter referred to as the “Agreement”) made and entered into as of May 2, 2005 (hereinafter referred to as the “Effective Date”) by and between DAIICHI SUNTORY PHARMA CO., LTD., a corporation organized and ex...

18 Oct 2004 8-K/A: Completion of Acquisition or Disposition of Assets

As previously reported in the Current Report on Form 8-K filed by the Registrant with the Commission on June 2, 2004 (the “Prior Report”), on May 18, 2004, Registrant completed its acquisition of the business of making, manufacturing, ma...

02 Aug 2004 8-K/A: Completion of Acquisition or Disposition of Assets

We consent to the incorporation by reference in the Registration Statements (Form S-3 Nos. 333-116575, 333-108972 and 333-102066) of BioMarin Pharmaceutical, Inc. of our report dated July 19, 2004, with respect to the financial statement...

03 Nov 2003 8-K/A: Other Events

Excerpted Transcript of the Company’s conference call on August 5, 2003, previously filed with the Commission on August 8, 2003 as Exhibit 99.1 to the Company’s Current Report on Form 8-K, which is incorporated herein by reference.

03 Nov 2003 8-K/A: Other Events

On September 22, 2003, BioMarin Pharmaceutical Inc. (the “Company”), issued a press release announcing the termination of it Phase 3a study of Neutralase and the termination of the Neutralase program for all indications. The Company’s pr...

18 Oct 2002 8-K/A: Financial Statements and Exhibits

The Audited Financial Statements of Glyko Biomedical Ltd. as of and for the Year Ended December 31, 2001.

18 Jun 2002 8-K/A: Changes in Registrant's Certifying Accountant

Office of the Chief Accountant Securities and Exchange Commission 450 Fifth Street, N.W. Washington, D.C. 20549

14 Jan 2002 8-K/A: Completion of Acquisition or Disposition of Assets

As previously reported in the Current Report on Form 8-K filed by the Registrant with the Commission on November 2, 2001 as amended and restated by Form 8-K/A filed by the Registrant with the Commission on November 15, 2001 (the "Prior R...

15 Nov 2001 8-K/A: Completion of Acquisition or Disposition of Assets

On October 31, 2001, the Registrant completed its acquisition of the rights to all of the pharmaceutical assets of IBEX Technologies Inc., IBEX Pharmaceuticals Inc., IBEX Technologies LLC, IBEX Technologies Corp. and Technologies IBEX R&...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support